The drug Osphena (ospemifene) has just been approved by the U.S. Food and Drug Administration for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) that causes pain during sexual intercourse in postmenopausal women. Dyspareunia occurs during menopause when estrogen levels drop to a level that causes vaginal atrophy, which is essentially the inflammation of the vagina due to shrinking and thinning of vaginal tissue. As a result, when women with vaginal atrophy engage in sexual intercourse it can be very painful and troublesome... via Health News from Medical News Today Read More Here..
No comments:
Post a Comment